Given its role in shaping the TME and influencing immune cell infiltration, IGF2BP2 may serve as a potential therapeutic target for enhancing the efficacy of immunotherapy in bladder cancer. This evidence concerns the gene IGF2BP2 and urinary bladder carcinoma.